Published in Drug Metab Dispos on May 01, 2003
Overcoming drug resistance by regulating nuclear receptors. Adv Drug Deliv Rev (2010) 1.10
Functional evolution of the pregnane X receptor. Expert Opin Drug Metab Toxicol (2006) 0.96
Role of pregnane X receptor in chemotherapeutic treatment. Cancer Chemother Pharmacol (2014) 0.79
Small-molecule modulators of the constitutive androstane receptor. Expert Opin Drug Metab Toxicol (2015) 0.77
Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro. Toxicol In Vitro (2017) 0.75
PXR variants: the impact on drug metabolism and therapeutic responses. Acta Pharm Sin B (2016) 0.75
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab (2005) 9.14
Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev (2003) 3.74
The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev (2002) 2.95
Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol (2002) 2.94
Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem (2001) 2.70
Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest (2003) 2.51
Orphan nuclear receptor LRH-1 is required to maintain Oct4 expression at the epiblast stage of embryonic development. Mol Cell Biol (2005) 2.32
Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem (2003) 2.28
Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. Mol Endocrinol (2008) 1.85
Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol (2004) 1.79
Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol (2002) 1.67
The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. J Biol Chem (2004) 1.65
2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry (2003) 1.55
Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J Nutr (2003) 1.45
The pharmacokinetics of acyl, des-acyl, and total ghrelin in healthy human subjects. Eur J Endocrinol (2013) 1.36
The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol (2007) 1.29
Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription. Mol Endocrinol (2004) 1.17
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther (2005) 1.16
Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate (2007) 1.14
Pregnenolone-16alpha-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms. Biochem J (2005) 1.11
Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J Pharmacol Exp Ther (2004) 1.11
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics (2002) 1.10
Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature. Expert Opin Ther Pat (2010) 1.09
Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res (2009) 1.07
Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver. J Lipid Res (2012) 1.05
Liver receptor homolog 1 is a negative regulator of the hepatic acute-phase response. Mol Cell Biol (2006) 1.04
The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? Mol Pharmacol (2008) 1.01
Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos (2002) 0.99
The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother Pharmacol (2008) 0.99
Cannabinoid receptor I activation markedly inhibits human decidualization. Mol Cell Endocrinol (2005) 0.99
Functional and structural comparison of PXR and CAR. Biochim Biophys Acta (2003) 0.99
Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. Chemotherapy (2007) 0.97
Transgenic mouse models of human CYP3A4 gene regulation. Mol Pharmacol (2003) 0.95
Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res (2004) 0.93
Prolactin suppresses glucocorticoid-induced thymocyte apoptosis in vivo. Endocrinology (2003) 0.92
Paralogous vitamin D receptors in teleosts: transition of nuclear receptor function. Endocrinology (2008) 0.92
Cellular and molecular studies on cisplatin-induced apoptotic cell death in rat kidney. Arch Toxicol (2003) 0.91
Effects of prolactin deficiency on myelopoiesis and splenic T lymphocyte proliferation in thermally injured mice. Endocrinology (2002) 0.89
Nitric oxide mediates increased P-glycoprotein activity in interferon-{gamma}-stimulated human intestinal cells. Am J Physiol Gastrointest Liver Physiol (2004) 0.89
Role of human pregnane X receptor in tamoxifen- and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells. Drug Metab Dispos (2008) 0.89
Single-dose and steady-state pharmacokinetic studies of S-equol, a potent nonhormonal, estrogen receptor β-agonist being developed for the treatment of menopausal symptoms. Menopause (2011) 0.88
Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol (2011) 0.87
Metabolites of progesterone and the pregnane X receptor: a novel pathway regulating uterine contractility in pregnancy? Am J Obstet Gynecol (2005) 0.87
Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. Cancer Chemother Pharmacol (2007) 0.86
Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J Pharmacol Exp Ther (2004) 0.86
Prolactin-regulated pim-1 transcription: identification of critical promoter elements and Akt signaling. Endocrine (2003) 0.85
Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother Pharmacol (2004) 0.84
Extracellular glucose concentration alters functional activity of the intestinal oligopeptide transporter (PepT-1) in Caco-2 cells. J Pharm Sci (2003) 0.84
Effects of prolactin level on burn-induced aberrations in myelopoiesis. Shock (2004) 0.84
Nuclear receptor regulation of genes involved in bile acid metabolism. Crit Rev Eukaryot Gene Expr (2002) 0.83
Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia (2003) 0.82
Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR. Biopharm Drug Dispos (2012) 0.81
Identification of HRPAP20: a novel phosphoprotein that enhances growth and survival in hormone-responsive tumor cells. Cancer Res (2004) 0.81
Cloning, tissue expression, and regulation of beagle dog CYP4A genes. Toxicol Sci (2006) 0.80
The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis. Cancer Chemother Pharmacol (2013) 0.80
Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes. Drug Metab Dispos (2011) 0.80
Preparation, characterization, and preliminary application of fibrinogen-coated olive oil droplets for the targeted delivery of docetaxel to solid malignancies. Cancer Res (2003) 0.79
Impact of ritonavir, atazanavir and their combination on the CYP3A4 induction potential of efavirenz in primary human hepatocytes. Drug Metab Lett (2010) 0.78
Bioavailability study of a 1200 mg miconazole nitrate vaginal ovule in healthy female adults. J Clin Pharmacol (2002) 0.78
Fibrinogen-coated droplets of olive oil for delivery of docetaxel to a fibrin(ogen)-rich ascites form of a murine mammary tumor. Clin Cancer Res (2004) 0.78
Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists. J Med Chem (2010) 0.78
Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR. Semin Liver Dis (2002) 0.78
Induction of olfactory mucosal and liver metabolism of lidocaine by 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Biochem Mol Toxicol (2002) 0.77
Pharmacokinetics of a slow-release formulation of soybean isoflavones in healthy postmenopausal women. J Agric Food Chem (2005) 0.76
Manipulation of olfactory tight junctions using papaverine to enhance intranasal delivery of gemcitabine to the brain. Drug Deliv (2013) 0.75
Prolactin Regulation of pim-1 Expression: Positive and Negative Promoter Elements1. Endocrinology (1999) 0.75
Metabolism and Pharmacokinetics of Anti-Cancer Drugs. Toxicol In Vitro (2006) 0.75
Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target. Ther Drug Monit (2015) 0.75
Stress and prolactin effects on bone marrow myeloid cells, serum chemokine and serum glucocorticoid levels in mice. Neuroimmunomodulation (2008) 0.75